DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
RA’ANANA, Israel and NEW YORK, May 10, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with a focus on uro-oncology, announced today the closing of its initial public offering on May 9, 2017 of an aggregate of 5,144,378 ordinary shares at a public offering price of $13.00 per share, including the exercise in full of the underwriters’ option to purchase an additional 671,005 shares, resulting in gross proceeds of approximately $66.9 million.
Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. acted as co-managers for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 3, 2017. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at [email protected]; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACT: Gary Titus, UroGen Pharma Ltd. 689 Fifth Avenue, 14th Floor New York, NY 10022 [email protected] 646-768-9531 Stephanie Carrington, ICR, Inc. 685 Third Avenue, 2nd Floor New York, NY 10017 [email protected] 646-277-1282
